INTENSITY THERAPEUTICS, INC.
INTSDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Sarcoma,Soft Tissue
1 drug in this indication
Breast Cancer
1 drug in this indication
triple-negative breast cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in INTENSITY THERAPEUTICS, INC.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in INTENSITY THERAPEUTICS, INC.'s (INTS) pipeline across Phase 3, Phase 2. Its lead program is Eribulin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is INTENSITY THERAPEUTICS, INC.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for INTENSITY THERAPEUTICS, INC. (INTS) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track INTS biotech catalysts?→
Add INTS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow INTENSITY THERAPEUTICS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.